Background
2009.8 - present Professor, Beijing Institute of Genomics, Chinese Academy of Sciences, China
2008.7-2009.8 Postdoctoral Scholar/Research Associate, Pharmacogenetics Anticancer Agents Research Group, University of Chicago, USA
2005.7 - 2008.7 Postdoctoral Fellow, Department of Medicine, Section of Hematology/Oncology, University of Chicago, USA
1999 - 2005 Ph.D, College of Life Sciences, Peking University, Beijing, China
Research interests
MicroRNA is a class of small non-protein-coding RNAs which has being a research hotspot in the biological fields because of its universality, complexity and significance, especially its key role in the cancerogenesis and development. Our main work is to study the regulation mechanism of microRNA expression in different type of leukemia. The methylation status, CNV and the histone modification in the gene regulatory region were analyzed by microarray and the high-throughput DNA/RNA sequencing technology. Simultaneously, we employed hemopoietic stem cell, RNA-interference, and the transgenic mice model to study the function of microRNA and its target genes in the development of leukemia and the differentiation of the hematopoiesis.
Pharmacogenetics and Pharmacogenomics lay the foundation for individualized medicine, which integrate genetics, genomics, bioinformatics, clinical medicine and the pharmacology. Our work is to determine the association of gene polymorphism, differential gene expression and individual drug response or drug toxicity of different anticancer agents by genome-wide association study, which provided the evidence for clinical trials in translational medicine.
1. The role of non-coding RNAs (microRNAs and long non-coding RNAs) in leukemogenesis, tumor development and drug resistance.
2. The sorting mechanism of tumor exosomal RNAs and novel biomarker identification for precision medicine.
3. The regulation role of intestinal microbiota in metabolic diseases.
Selected Publications and Books
1. Jerome Mertens, Qiu-Wen Wang, et al. Shuangli Mi. Differential responses to lithium in hyperexcitable neurons from patients with bipolar disorder. Nature. 527,95-9(2015).
2. Zhang J, Li S, Li L, Li M, Guo C, Yao J, Mi SL*. Exosomal MicroRNA: Trafficking, sorting and function. Genomics Proteomics Bioinformatics. 2015, 13(1):17-24.
3. Zhu X, He F, Zeng H, Ling S, Chen A, Wang Y, Yan X, Wei W, Pang Y, Cheng H, Hua C, Zhang Y, Yang X, Lu X, Cao L, Hao L, Dong L, Zou W, Wu J, Li X, Zheng S, Yan J, Zhang L, Mi S, Wang X, Zhang L, Zou Y, Chen Y, Geng Z,Wang J, Zhou J, Liu X, Wang J, Yuan W, Huang G, Cheng T, Wang QF. Identification of functional cooperative mutations of SETD2 in human acute leukemia. Nat Genet. 2014 Mar; 46(3):287-93
4. Mi S, Zhang J, Zhang W, Huang RS. Circulating microRNAs as biomarkers for inflammatory diseases. MicroRNA. 2013, 2(1):64-72.
5. Wang QF, Wu G, Mi S, He F, Wu J, et al. MLL Fusion Proteins Preferentially Regulate a Subset of Wild Type MLL Target Genes in the Leukemic Genome. Blood. 2011, 117: 6895-6905
6. Wen Y, Gamazon ER, Bleibel WK, Wing C, Mi S, et al. An eQTL-based method identifies CTTN and ZMAT3 as pemetrexed susceptibility markers. Hum Mol Genet. 2011, 21: 1470-1480
7. Tao Y, Ruan J, Yeh SH, Lu X, Wang Y, et al. Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome data. P Natl Acad Sci USA. 2011, 108: 12042-12047
8. Mi S, Li Z, Chen P, He C, Cao D, et al. Aberrant overexpression and function of the miR-17-92 cluster in MLL-rearranged acute leukemia. P Natl Acad Sci USA. 2010, 107: 3710-3715
9. Huang RS, Johnatty SE, Gamazon ER, Im HK, Ziliak D, et al. Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res. 2011, 17: 5490-500.
10. Stark AL, Zhang W, Mi S, Duan S, O'Donnell PH, et al. Heritable and non-genetic factors as variables of pharmacologic phenotypes in lymphoblastoid cell lines. Pharmacogenomics J. 2010, 10: 505-512
11. Huang RS, Mi S. Candidate genes pharmacogenetics of anti-cancer agents. Pharmacogenomics, 2009, 10 (5): 719-720
12. Hartford C, Duan S, Delaney S, Mi S, Kistner E, et al. Population Specific Genetic Variants Important in Susceptibility to Cytarabine Arabinoside Cytotoxicity. Blood. 2009, 113: 2145-2153
13. Duan S, Huang RS, Zhang W, Mi S, Bleibel WK, et al. Expression and Alternative Splicing of Folate Pathway Genes in HapMap Lymphoblastoid Cell Lines. Pharmacogenomics, 2009. 10: 549-563
14. Duan S *, Mi S *, Zhang W, Dolan M.E. Comprehensive analysis of the impact of SNPs and CNVs on human microRNAs and their regulatory genes. RNA biology. 2009, 6: 412-425. (* contribute equally)
15. Li Z, Luo RT, Mi S, Sun M, Chen P, et al. Consistent deregulation of gene expression between human and murine MLL-rearrangement leukemias. Cancer Res. 2009, 69: 1109-1116
16. Li Z *, Lu J*, Sun M*, Mi S*, Zhang H, et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. P Natl Acad Sci USA. 2008, 105: 15535-15540 (* contribute equally)
17. Mi S, Lu J, Sun M, Li Z, Zhang H,et al. MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. P Natl Acad Sci USA. 2007, 104 : 19971-19976
18. Wang M, Xie H, Mi S, Chen J. Recent patents on the identification and clinical application of microRNAs and target genes. Recent Patents on DNA & Gene Sequences. 2007, 1 : 116-124
19. Zhang XY, Wu Y, Yan JY, Gao Y, Wang Y, et al. Y55 and D78 are crucial amino acid residues of a new IgE epitope on trichosanthin. Biochem Biophy Res Co. 2006, 343: 1251-1256
20. Mi SL, An CC, Wang Y, Chen JY, Che NY, et al. Trichomislin, a novel ribosome-inactivating protein, induces apoptosis that involves mitochondria and caspase-3. Archives of Biochemistry and Biophysics. 2005, 434: 258-265
21. Wang Y, Mi SL, Lou M, Gao Y, Chen ZL, et al. Enhanced Green Fluorescence protein tracks Trichosanthin in human choriocarcinoma cells as a feasible and stable reporter. Frontiers in Bioscience. 2005, 10: 2279-2284
Patent:
1. Mutants of Trichosanthin and related coding gene.200410074324.6
2. Mutants of Trichosanthin with Anti-Tumor Activity and Lowered Side-Effects. US2008261874/WO2006026906, USA
